Overview

Paclitaxel-Avelumab for Angiosarcoma

Status:
Recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

To investigate the efficacy of Avelumab when given in combination with paclitaxel as a first line treatment for the patients with inoperable angiosarcoma.

Phase:

Phase 2

Details

Lead Sponsor:

Sung Yong Oh

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Avelumab
Paclitaxel